Philadelphia’s Risperdal Litigation Nears End with Monumental $1.1 Billion Settlement Agreement
Philadelphia, PA — In what marks a significant resolution, nearly all lawsuits in Philadelphia involving the antipsychotic drug Risperdal have been settled for up to $1.1 billion. This settlement addresses claims that the drug, produced by Johnson & Johnson’s subsidiary Janssen Pharmaceuticals, led to adverse effects such as gynecomastia, a condition characterized by breast tissue enlargement in males. The legal battles, accumulating over years, primarily involved male plaintiffs who alleged that Risperdal, prescribed to treat schizophrenia and bipolar disorder, caused them to develop breasts after taking the medication. Many of the lawsuits also claimed that … Read more